Efficacy of Targeted Therapy in Genetic Subtypes of Aggressive Lymphoma – Module 3

Access Activity

Overview / Abstract:

Target Audience

This activity is designed to meet the educational needs of hematologists, oncologists, and other healthcare professionals involved in the diagnosis and treatment of patients with blood cancers.

Program Overview

This activity provides an overview of molecular and clinical subtypes of lymphoma and the mechanisms by which targeted therapies work for molecular subtypes.

Learning Objective

Upon completion of this activity, participants should be better able to:

Summarize the efficacy of targeted therapy in genetic subtypes of aggressive lymphoma.

Expiration

Mar 02, 2023

Discipline(s)

Physician CME

Format

Online

Credits / Hours

1.0 AMA PRA Category 1 Credit(s)™

Accreditation

ACCME

Presenters / Authors / Faculty

Faculty

FACULTY_NAME
Louis M. Staudt, MD, PhD
Chief, Lymphoid Malignancies Branch
Director, Center for Cancer Genomics
National Cancer Institute
Bethesda, MD

Sponsors / Supporters / Grant Providers

The Leukemia & Lymphoma Society

Keywords / Search Terms

Relias LLC Relias LLC., FreeCME., Leukemia , Lymphoma Free CE CME

Access Activity

CORE Higher Education Group, CESearchEngine.com, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the CESearchEngine.com website or within our mobile apps.CORE Higher Education Group, CESearchEngine.com, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or within our mobile apps. For complete details, please read the CESearchEngine.com Terms of Service. Site Map